SEC Form 4 · accession 0001358403-16-000238
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M. Spencer
Officer — Chief Scientific Officer
Period of report
Jul 27, 2016
Accepted (ET)
Jul 29, 2016 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 27, 2016 | S | 10,000 | $15.00 | D | 176,082 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 21, 2016 by the Reporting Person.
- F2Includes 1,523 shares acquired under the Issuer's Employee Stock Purchase Plan on June 10, 2016.